ARTICLE
7 May 2024

LDT Oversight Gets Long-Awaited FDA Final Rule

M
Mintz

Contributor

Mintz is a general practice, full-service Am Law 100 law firm with more than 600 attorneys. We are headquartered in Boston and have additional US offices in Los Angeles, Miami, New York City, San Diego, San Francisco, and Washington, DC, as well as an office in Toronto, Canada.
Of Counsel Benjamin Zegarelli spoke with MD+DI on the FDA's updated regulations to classifying laboratory-developed tests (LDTs) as medical devices under the Federal Food, Drug, and Cosmetic Act...
United States Food, Drugs, Healthcare, Life Sciences

Of Counsel Benjamin Zegarelli spoke with MD+DI on the FDA's updated regulations to classifying laboratory-developed tests (LDTs) as medical devices under the Federal Food, Drug, and Cosmetic Act (FD&C Act).

Benjamin said, "Many LDT developers will become subject to FDA regulations that are already applicable to other medical devices, including other in vitro diagnostic devices, such as requirements to register manufacturing facilities and list commercial devices with FDA, applying compliant labeling to commercial devices, reporting certain device adverse events and malfunctions, and implementing a compliant quality system."

SOURCE

MD+DI

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See More Popular Content From

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More